Misset J L, Marnich R, Michel G, George M, Wolff J P, Mathé G
Nouv Presse Med. 1980 Jun 28;9(28):1937-9.
Forty patients with adenocarcinoma of the ovary (including 34 in stages III and IV) underwent a "second look" surgical operation after a first course of chemotherapy. The operation, which carried negligible morbidity, demonstrated complete remission in 27,5% of the cases; whenever necessary and possible achieved complete remission by surgical excision; and helped in establishing a second course of chemotherapy or chemo-immunotherapy. This therapeutic strategy seems to have had overall favourable repercussions on the patients' short- and mid-term survical. Long-term results cannot yet be assessed, but the knowledge of late failures suggests that applying intensive chemotherapy or, preferably, chemo-immunotherapy after the "second look", or even reserving potent cytostatic drugs for that period, could be beneficial. From the very favourable survival rate in patients found on second look to have complete remission, one may conclude that surgically confirmed remission should be considered as the primary target of the initial treatment.
40例卵巢腺癌患者（包括34例Ⅲ期和Ⅳ期患者）在接受第一疗程化疗后接受了“二次探查”手术。该手术的发病率可忽略不计，27.5%的病例显示完全缓解；必要时尽可能通过手术切除实现完全缓解；并有助于确定第二疗程的化疗或化疗免疫治疗。这种治疗策略似乎对患者的短期和中期生存产生了总体有利影响。长期结果尚无法评估，但对晚期复发的了解表明，在“二次探查”后应用强化化疗或更优选化疗免疫治疗，甚至在该阶段保留强效细胞毒性药物可能是有益的。从二次探查发现完全缓解的患者非常有利的生存率来看，可以得出结论，手术证实的缓解应被视为初始治疗的主要目标。
